Abiopharma

News list

KIORA PHARMACEUTICALS INC (KPRX)

SEC News
April 02, 2026, 20:44 UTC

(75% Positive) KIORA PHARMACEUTICALS INC (KPRX) Announces Enrollment Update for Eric Due to Patient Enrollment Issues, Regulatory Process, Safety Review

Full text

News bot April 2, 2026, 8:45 p.m.

📋 KIORA PHARMACEUTICALS INC (KPRX) - Clinical Trial Update

Filing Date: 2026-04-02

Accepted: 2026-04-02 16:44:29

Event Type: Clinical Trial Update

Event Details:

KIORA PHARMACEUTICALS INC (KPRX) Announces Clinical Trial Update KIORA PHARMACEUTICALS INC (KPRX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: Eric, search
Diseases/Conditions: his commitment, his successor
Clinical Stage: clinical trial, Phase 2
Collaboration: CRO

🔬 Clinical Development Pipeline (KIORA PHARMACEUTICALS INC):

Product	Type	Development Stage	Therapeutic Area	Source
KIO-104	DRUG	Phase PHASE2	Macular Edema	ClinicalTrials.gov
50 μg KIO-301	DRUG	Phase PHASE2	Retinitis Pigmentosa	ClinicalTrials.gov
KIO-301	DRUG	Phase PHASE1	Retinitis Pigmentosa	ClinicalTrials.gov
Placebo (Sterile Saline or Balanced Salt Solution)	OTHER	Phase PHASE2	Retinitis Pigmentosa	ClinicalTrials.gov
KIO-101	DRUG	Phase PHASE2	Dry Eye Disease	ClinicalTrials.gov
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)	DRUG	Phase PHASE2	Persistent Corneal Epithelial Defect	ClinicalTrials.gov
100 μg KIO-301	DRUG	Phase PHASE2	Retinitis Pigmentosa	ClinicalTrials.gov
Placebo (Sterile Saline)	OTHER	Phase PHASE2	Retinitis Pigmentosa	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: KIORA PHARMACEUTICALS INC
Ticker Symbol: KPRX